ValuEngine upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a strong sell rating to a sell rating in a research report sent to investors on Thursday.
ARWR has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed a hold rating and issued a $2.00 target price (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. William Blair raised shares of Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a research report on Monday, September 18th. Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 target price on the stock in a research report on Monday, November 27th. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Jefferies Group reaffirmed a hold rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $3.17.
Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at $3.49 on Thursday. Arrowhead Pharmaceuticals has a 1 year low of $1.20 and a 1 year high of $4.54. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03.
COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals (ARWR) Upgraded by ValuEngine to Sell” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/04/arrowhead-pharmaceuticals-arwr-upgraded-by-valuengine-to-sell.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Arrowhead Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arrowhead Pharmaceuticals Inc and related companies.